A Comparison of Two Doses of Intranasal Dexmedetomidine for Premedication in Children
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT02459509 |
|
Recruitment Status : Unknown
Verified April 2016 by The University of Hong Kong.
Recruitment status was: Recruiting
First Posted : June 2, 2015
Last Update Posted : April 18, 2016
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Anxiety, Separation | Drug: Dexmedetomidine | Phase 4 |
Dexmedetomidine is a selective alpha-2 adrenoreceptor agonist that has sedative, anxiolytic and analgesic properties without causing respiratory depression. It has been administered safely and effectively via a number of routes including as an intravenous infusion, intramuscularly, intranasally, buccally and orally .
Yuen et al established that the median time of onset of sedation is 25-30 minutes, making it an ideal agent for preoperative sedation. The same group also studied doses of 1 mcg/kg and 2 mcg/kg as a sedative premedication and found that the success rates of appropriate sedation at induction in children aged 1 to 8 years were 53% and 66% respectively, with a dose related increase in successful sedation.
Much higher doses of dexmedetomidine have also been used safely. Administered intravenously, 3mcg/kg of dexmedetomidine has been shown to provide satisfactory sedation for paediatric MRI in 97% of cases, without adverse effects.
The investigators aim to show that high dose intranasal dexmedetomidine is a safe, effective and an easily administered sedative premedication.
The investigators hypothesise that 4mcg/kg compared to 2mcg/kg of intranasal dexmedetomidine will lead to at least a 20% increase in the proportion of satisfactorily sedated patients at the time of anaesthesia induction.
The primary outcome will be the proportion of children with satisfactory sedation at the time of anaesthesia induction.
Suitable patients will be identified from the theatre lists and consent will be sought from their legal guardians during preassessment clinic or during their anaesthetic preoperative assessment on the ward.
In a previous study, 66% of children aged 1-5 years were satisfactorily sedated at the time of induction with 2 mcg/kg of intranasal dexmedetomidine. In order to find a 20% difference with 4 mcg/kg of dexmedetomidine, the investigators' sample size needs to be 140 (70 in each group), for a power of 0.8 and a 5% false positive rate.
The demographic data will be analysed by t test and chi-square test. The proportions of satisfactory sedation will be analysed by chi-square test. The onset sedation time and duration of sedation will be analysed by survival analysis. The vital signs over times will be expressed by percentage changes from baseline and estimated by mean and standard errors. A p-value<0.05 will be considered statistically significant.
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 140 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) |
| Primary Purpose: | Treatment |
| Official Title: | A Comparison of Two Doses of Intranasal Dexmedetomidine for Premedication in Children - a Double- Blind Randomised Controlled Trial |
| Study Start Date : | June 2015 |
| Estimated Primary Completion Date : | May 2016 |
| Estimated Study Completion Date : | May 2016 |
| Arm | Intervention/treatment |
|---|---|
|
Active Comparator: Dexmedetomidine 2 mcg/kg
2 mcg/kg dexmedetomidine given intranasally once at least 30 minutes before anaesthetic induction
|
Drug: Dexmedetomidine
Either 2mcg/kg or 4mcg/kg of intranasal dexmedetomidine will be given to assess efficacy of preoperative sedation
Other Name: Precedex |
|
Active Comparator: Dexmedetomidine 4 mcg/kg
4 mcg/kg dexmedetomidine given intranasally once at least 30 minutes before anaesthetic induction
|
Drug: Dexmedetomidine
Either 2mcg/kg or 4mcg/kg of intranasal dexmedetomidine will be given to assess efficacy of preoperative sedation
Other Name: Precedex |
- Satisfactory sedation [ Time Frame: From 30 minutes post drug administration to induction of anaesthesia (average 30 minutes) ]The primary outcome will be the proportion of children with satisfactory sedation at the time of anaesthesic induction.
- Time to satisfactory sedation [ Time Frame: From time of drug administration to when Observer's Assessment of Alertness/ Sedation Score is 2 or less (from 0 minutes to 30 minutes) ]Time taken from drug administration to when the child's sedation level is that of only responding after mild prodding or shaking
- Blood pressure [ Time Frame: From drug administration to end of anaesthesia (on average 1 to 3 hours) ]Blood pressure will be taken every 5 minutes
- Heart rate [ Time Frame: From drug administration to end of anaesthesia (on average 1 to 3 hours) ]Heart rate will be taken every 5 minutes
- Oxygen saturations [ Time Frame: From drug administration to end of anaesthesia (on average 1 to 3 hours) ]Oxygen saturations will be taken every 5 minutes
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 6 Months to 5 Years (Child) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- All children of American Society of Anesthesiologists (ASA) physical status classification I or II (healthy) between the ages of 6 months and 5 years undergoing surgery at Queen Mary Hospital
Exclusion Criteria:
- Any patient receiving other sedative premedication, allergy to dexmedetomidine, organ dysfunction, cardiac arrhythmia and congenital heart disease.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02459509
| Contact: Sophie E Liu, MBBS | 852 55086630 | sophieliu@doctors.org.uk | |
| Contact: Theresa Hui, MBBS | 852 95368149 | huiwct@ha.org.hk |
| Hong Kong | |
| Queen Mary Hospital | Recruiting |
| Hong Kong, Hong Kong | |
| Contact: Sophie E Liu, MBBS 55086630 sophieliu@doctors.org.uk | |
| Contact: Theresa Hui, MBBS 95368149 huiwct@ha.org.hk | |
| Principal Investigator: Sophie E Liu, MBBS | |
| Sub-Investigator: Theresa Hui, MBBS | |
| Sub-Investigator: Grace Wong, MBBS | |
| Sub-Investigator: Vivian Yuen, MBBS | |
| Sub-Investigator: Michael G Irwin, MBChB | |
| Sub-Investigator: Silky Wong, MBBS | |
| Principal Investigator: | Sophie E Liu, MBBS | Hong Kong University |
| Responsible Party: | The University of Hong Kong |
| ClinicalTrials.gov Identifier: | NCT02459509 |
| Other Study ID Numbers: |
UW 15-105 |
| First Posted: | June 2, 2015 Key Record Dates |
| Last Update Posted: | April 18, 2016 |
| Last Verified: | April 2016 |
|
Sedation dexmedetomidine pediatric preoperative period |
|
Anxiety, Separation Anxiety Disorders Mental Disorders Neurodevelopmental Disorders Dexmedetomidine Hypnotics and Sedatives Central Nervous System Depressants Physiological Effects of Drugs Analgesics, Non-Narcotic |
Analgesics Sensory System Agents Peripheral Nervous System Agents Adrenergic alpha-2 Receptor Agonists Adrenergic alpha-Agonists Adrenergic Agonists Adrenergic Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action |